Clinical Trials Logo

Filter by:
NCT ID: NCT01447394 Withdrawn - Clinical trials for Hepatitis C Virus (HCV)

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Start date: March 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if 48 weeks of therapy with Pegylated Interferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Pegylated Interferon Alfa-2a plus Ribavirin.

NCT ID: NCT01436292 Withdrawn - Clinical trials for Second or Third Degree Burns

Hypoalbuminemia in Burn Patients

Halburns
Start date: September 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether 5% human albumin solution, given to correct hypoalbuminemia, could improve organ dysfunction in burn patients as assessed by a change in the SOFA score from baseline to day 7 (or before if the patient is discharged from the ICU or died).

NCT ID: NCT01433003 Withdrawn - Clinical trials for Hemolytic Uremic Syndrome

The Plasma Large-Volume Exchange RCT

PLEX-RCT
Start date: April 2012
Phase: Phase 3
Study type: Interventional

Thrombotic thrombocytopenia purpura / hemolytic uremic syndrome (TTP/HUS) is a rare, life-threatening disorder. TTP/HUS causes multiple blood clots to form, which prevents blood from reaching the brain and kidneys. TTP/HUS affects 3-5 people per million per year. Anyone can develop TTP/HUS, but it is most common among 30-40 year olds, and women are twice as likely as men to acquire the condition. TTP/HUS sometimes develops as a result of medication use, pregnancy or cancer; however, for the majority of patients (80%) the cause of TTP/HUS is unknown. In 1991, researchers discovered that plasma exchange was superior to plasma infusion in treating idiopathic TTP/HUS. During plasma exchange the patient's blood plasma is removed and replaced with healthy blood plasma. Without plasma exchange, the survival rate for TTP/HUS is extremely low, with fewer than 5% of patients surviving. Treating TTP/HUS with plasma exchange improved the survival rate to 80%. Although this represents a dramatic improvement, researchers are still searching for methods to improve survival. No major advances in treating TTP/HUS have occurred in the past 20 years. Recent research suggests that high-dose plasma exchange may improve the survival of TTP/HUS patients. The investigators will conduct a randomized controlled trial to test whether treating TTP/HUS patients with high-dose versus standard-dose plasma exchange improves the treatment response. The investigators will recruit 150 patients with TTP/HUS from 9 centres across Canada over three years. The investigators will evaluate whether high-dose plasma exchange improves the treatment response, survival, and whether it reduces the number and volume of plasma exchange procedures and duration of hospital stay.

NCT ID: NCT01422928 Withdrawn - Clinical trials for Gastrointestinal Neoplasms

Acupuncture for the Immune System in Radiation Cancer Patients

Start date: December 2010
Phase: Phase 3
Study type: Interventional

Purpose/Goal: To investigate how long course radiation therapy (RT), both with or without chemotherapy, affects the immune system, and to determine if acupuncture can modify these effects in patients undergoing curative radiation therapy for gastrointestinal (GI) or genitourinary (GU) cancers. Clinical or Research Questions: 1. Does RT reduce immune biomarkers in treated subjects? 2. Which biomarkers are most affected by treatment? 3. Is acupuncture a feasible option to help ameliorate any biomarker effects? 4. Does RT affect subject symptoms? 5. Is acupuncture a feasible option to help ameliorate any symptom effects?

NCT ID: NCT01410708 Withdrawn - Breast Cancer Clinical Trials

TORI 104 Pre-Surgical Dasatinib

Start date: n/a
Phase: Phase 2
Study type: Interventional

This study will examine the anti-tumor activity, safety and tolerability of dasatinib in adjuvant breast cancer patients in a pre-surgical setting.

NCT ID: NCT01405014 Withdrawn - Clinical trials for Marital Relationship

Outcome Study of Hold Me Tight Program With Acquired Brian Injury (ABI) Populations

Start date: January 2012
Phase: Phase 3
Study type: Interventional

The objectives of this research pilot project are to assess the efficacy of the Hold Me Tight Relationship Enhancement Program with couples where at least one partner has an acquired brain injury.

NCT ID: NCT01400009 Withdrawn - Clinical trials for HMG COA Reductase Inhibitor Adverse Reaction

Vitamin D Replacement in Statin-Induced Myopathy

Start date: October 2010
Phase: N/A
Study type: Interventional

Pretreating people with replacement doses of vitamin D will allow them to tolerate Statin medications that have caused muscle pain for them in the past.

NCT ID: NCT01387126 Withdrawn - Obesity Clinical Trials

Effects of a High Viscosity Dietary Fibre, as Part of a Medically Supervised Weight Management Program

Start date: n/a
Phase: Phase 3
Study type: Interventional

The aim of this study is to investigate whether the supplementation of a medically supervised weight management program with a novel fibre supplement, improves body weight, body composition, and laboratory measurements in overweight and obese individuals. All subjects will participate in the medical weight management program however the intervention group will have 5 grams of a novel fibre supplemented to each meal while the control group will not.

NCT ID: NCT01384500 Withdrawn - Barotrauma Clinical Trials

The Ornge Comparison of Tracheal Occlusion Pressures to Ensure Safety Trial

OCTOPUS
Start date: July 2011
Phase: N/A
Study type: Interventional

Patients who are intubated (breathing tube in windpipe) are often transported by air ambulance. Changes in atmospheric pressure during flight may cause pressure increases in the air-filled cuff holding the tube in the windpipe. Studies show that more than half the patients had potentially harmful pressures in the cuff during flight. High pressures lead to complications, such as injury to the windpipe. To avoid injury, cuff pressures must be kept at a safe level. There are many ways to avoid unsafe cuff pressures. One is to inflate the cuff with sterile fluid instead of air. Fluids are not subject to changes in atmospheric pressure. Using fluid, instead of air, in the cuff causes less pressure increases and less windpipe injury. The use and safety profile of this during transport by air ambulance has not been studied. This study compares tracheal tube cuff pressures, filled with air or fluid, at routine flying altitudes during patient transports by air ambulance.

NCT ID: NCT01382849 Withdrawn - Clinical trials for Cerebral Amyloid Angiopathy

F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)

Start date: August 2011
Phase: N/A
Study type: Observational

Florbetapir F 18 is an experimental radioactive drug that may allow doctors to image changes in the brain using a PET (Positron Emission Tomography) scanner. The purpose of this study is to evaluate the imaging characteristics of, Florbetapir F 18 (also known as 18F-AV-45) in patients who have previously undergone bleeding in their brains. Florbetapir F 18 binds to amyloid-ß peptide (Aß) that accumulates in the brains of patients with bleeding. These accumulations are called amyloid plaques and when extensive are labeled cerebral amyloid angiopathy (CAA). Florbetapir F 18 sticks to the amyloid plaques in the brain and emits a low level of gamma rays which can be detected by a PET camera. MRI detected microbleeds have been identified as markers of clinically silent hemorrhage from bleeding-prone vessels. Another imaging marker of vessel damage and risk of bleeding is the spot sign (SS). Finally, certain genetic signatures (ApoE genotype) have been shown to be associated with Aß deposition in the brain or predispose patients to higher risks of bleeding. This research study will explore the interactions of these factors and understand the physiology of intracerebral bleeding.